Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2010
10/05/2010US7807684 HIV reverse transcriptase inhibitors
10/05/2010US7807683 N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
10/05/2010US7807682 Pyridyl cyanoguanidine compounds
10/05/2010US7807681 Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
10/05/2010US7807680 Controlled release sterile injectable aripiprazole formulation and method
10/05/2010US7807678 Peptidomimetics of biologically active metallopeptides
10/05/2010US7807677 1-[N'-[(R)-4-Hydroxy-4-((1S,2R)-2-hydroxy-indan-1-yl]carbamoyl)-5-phenyl-pentyl]-N'-(4-pyridin-4-yl-benzyl)-hydrazinocarbonyl]-2,2-dimethyl-propyl-carbamic acid methyl ester; effective against strains resistant to squinavir, ritonavir, and indinavir; improved bioavailability
10/05/2010US7807676 1-(4-fluoro-7-(3-methyl-1H-pyrazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-(4-(1-phenyl-1H-tetrazol-5-yl)piperazin-1-yl)ethane-1,2-dione; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus; AIDS; immunomodulators; with AIDS antiviral, antiinfective agent, HIV entry inhibitor
10/05/2010US7807675 Hyaluronic acid-methotrexate conjugate
10/05/2010US7807674 such as 2-[3,5-Dichloro-4-(5-isopropyl-1-methyl-6-oxo-1,6-dihydro-pyridazin-3-ylmethyl)-phenyl]-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazine-6-carbonitrile, useful for the treatment of obesity, hyperlipemia, hypercholesterolemia, diabetes, fatty liver, atherosclerosis, cancer and cardiovascular disorders
10/05/2010US7807673 protein tyrosine kinase inhibitors such as N-[3-(3-{2-[(2-Methyl-1,2,3,4-tetrahydro-7-isoquinolinyl)amino]-4-pyrimidinyl}pyrazolo[1,5-a]pyridin-2-yl)phenyl]-2-(2-thienyl)acetamide, used for treating breast cancer in a human; anticarcinogenic agents
10/05/2010US7807672 Compounds that are ERK inhibitors
10/05/2010US7807671 viricides such as 1-(7-bromo-4-fluoro-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-(4-(1-phenyl-1H-tetrazol-5-yl)piperazin-1-yl)ethane-1,2-dione , used for the treatment of HIV and AIDS
10/05/2010US7807670 viricides used for for treating a human papillomavirus (HPV) viral infections, for inhibiting HPV DNA replication or for preventing prenatal transmission of HPV from mother to baby by administering to the mother prior to giving birth
10/05/2010US7807669 Peroxisome proliferator-activated receptor type gamma (PPAR- gamma) modulators such as (S)-3-{3'-[(benzoylmethylamino)methyl]biphenyl-4-yl}-2-(1-methyl-3-oxo-3-phenylpropenylamino)propionic acid, suited for use in dermatology, immunology, cardiovascular diseases and/or hyperlipemia
10/05/2010US7807668 Anti-inflammatory compounds
10/05/2010US7807667 4-(5-Benzo[1,3]dioxol-5-yl-[1,3,4]oxadiazol-2-yl)-1,4-diaza-bicyclo[3.2.2]-nonane or fumaric acid salt; diseases or disorders related to smooth muscle contraction, endocrine diseases, neurodegenerative disorders, inflammation, pain, and withdrawal symptoms caused by the termination of substance abuse
10/05/2010US7807666 (phenyl(1,3)diazepyl-2-one-piperidyl)-[1(benzyl)-1(piperidyl)-methyl] ester derivatives; calcitonin gene related peptide inhibitor; disregulation the brain-gut axis, as a result of sensitization of visceral afferent mechanisms, most likely peptidergic C-fibers containing CGRP; gastrointrestinal disorder
10/05/2010US7807664 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or salt thereof
10/05/2010US7807663 Therapeutic agents for diabetes
10/05/2010US7807662 inducing apoptosis in malignant cells selected from breast cancer cells, non-small cell lung cancer cells, myeloma cells and colon tumor cells, comprising administering a platinum (IV) hexachloride complex with 1-[4-(1-hydroxypropyl)piperazin-1-yl]propan-1-ol; STAT proten inhibitors
10/05/2010US7807660 Tetracycline compounds for treatment of Cryptosporidium parvum related disorders
10/05/2010US7807659 5-Fluoro-4-oxo-3-[1-(substituted-carbonyl)-2-piperidinecarboxamido]-pentanoic acid derivatives such as [3S/R (2S)]-5-Fluoro-4-oxo-3-[1-(2-phenyl-thiazole-4-carbonyl)-2-piperidinecarboxamido]-pentanoic acid, used for the treatment of bone disorders, inflammatory, autoimmune and degenerative diseases
10/05/2010US7807658 Administering an optionally substituted 3-aminopropylphosphinic acid (3-amino-2-fluoropropyl)phosphinic acid, 3-amino-2-oxopropyl)phosphinic acid); irritable bowel syndrome
10/05/2010US7807657 comprising liquid (A) which is aqueous solution containing hyaluronic acid ester derivative and buffered to pH of 4.5 to 6.5, and liquid (B) which is aqueous solution having a buffering power that when mixed with liquid (A), the mixed liquid has a pH range from 6.8 to 7.8, kept separate from eachother
10/05/2010US7807656 Pharmaceutical applications of hyaluronic acid preparations
10/05/2010US7807655 uridine-5'-monophosphate or cytidine-5'-monophosphate for the treatment of affections of the peripheral nervous system, particularly polyneuropathies, neuritides, and myopathies; for stimulating the regeneration of nerves
10/05/2010US7807654 Compositions and methods for treatment of mitochondrial diseases
10/05/2010US7807653 Nucleotide mimics and their prodrugs
10/05/2010US7807652 Antisense agents for use in treatment of diabetes and controlling blood lipid levels; gene expression inhibition; genes involved in glucose metabolism are glucose-6-phosphatase and glycogen synthase;steatohepatitis; decreasing hepatic triglyceride levels
10/05/2010US7807650 such as IBD and Crohn's disease; intrarectal administration of siNA compounds
10/05/2010US7807647 administering an antigene oligonucleotide that hybridizes under physiological conditions to the promoter region of a bcl-2 gene; anticarcinogenic agents for melanomas, pancreatic, colon, breast, bladder, lung, leukemia, prostate, lymphoma, and ovarian cancers; docetaxel
10/05/2010US7807640 stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or promote lipid transport and detoxification and inhibit osteoporosis; class A amphipathic helix when formulated with "D" amino acid residue(s) and/or having protected amino and carboxyl termini; atherosclerosis
10/05/2010US7807445 Antibiotic compound
10/05/2010US7807406 Fagopyritol synthase genes and uses thereof
10/05/2010US7807355 drug screening; identifying a therapeutic for decreasing intraocular pressure raised due to frizzled related protein (FRP) overexpression; contacting a trabecular meshwork cell expressing a Wnt pathway component or a frizzled related protein gene product with a test compound
10/05/2010US7807350 Methods for predicting irinotecan toxicity
10/05/2010US7807198 containing a polymer, a therapeutic agent, and a complexing agent, where the polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex; may be used to deliver a therapeutic agent in treatment of various disorders
10/05/2010US7807196 Using inert gas; controlling humidity
10/05/2010US7807195 Extended release formulation of venlafaxine hydrochloride
10/05/2010US7807194 Plasticizer, film former, bulking agent, and pH controlling agent;
10/05/2010US7807191 Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts
10/05/2010US7807185 applying to skin or mucous membrane of a mammal a composition comprising an extracellular product of a Pseudomonas lindbergii strain, an extracellular product of a Bacillus coagulans strain, and an anti-fungal agent selected from Amphotericin B, Carbol-Fuchsin, Ciclopirox, for example
10/05/2010US7807176 Polypeptide promoting vascular endothelial cell growth
10/05/2010US7807167 using an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin; treatment of multiple sclerosis or inflammatory disease of the gastrointestinal tract
10/05/2010US7807151 identifying a mammalian subject having an infection with said pathogenic Clostridium bacterium resistant to antibiotic, orally administering a therapeutically-effective concentration of Bacillus coagulans bacteria
10/05/2010US7807149 treatment of a bacterial infection characterized by biofilm formation; for Pseudomonas aeruginosa infections such as those in canine ears
10/05/2010US7807146 Recombinant Modified Vaccinia Ankara virus; encoding a polypeptide HER-2 antigen; administering tumoricidal dose of taxanes paclitaxel and docetaxel
10/05/2010US7807142 comprising interleukin-2 (IL-2); using an amino acid base sufficient to decrease aggregate formation of the polypeptide during storage of the composition, and a buffering agent ; mixture with amino acid and buffer
10/05/2010US7806924 Implantable structures for local vascular delivery of cladribine in combination with rapamycin for restenosis
10/05/2010CA2559023C Compositions with health and nutrition promoting characteristics, containing interesterified lipids and phytosterol, and related methods
10/05/2010CA2547745C Antiirritant or antiinflammatory cosmetic compositions
10/05/2010CA2530798C Synthesis and compositions of 2'-terminator nucleotides
10/05/2010CA2527974C Process for increasing liquid extraction from fabrics
10/05/2010CA2509605C Alpha-2-delta ligand to treat lower urinary tract symptoms
10/05/2010CA2456519C Oral compositions for the treatment of scalp disorders
10/05/2010CA2455167C New pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
10/05/2010CA2452638C Optimised formulation of tobramycin for aerosolization
10/05/2010CA2441331C Bicyclic guanidine derivatives and therapeutic uses thereof
10/05/2010CA2436233C Perylenequinones for use with immunotherapy agents
10/05/2010CA2434900C New use of iloperidone
10/05/2010CA2431705C Method for preparing submicron particle suspensions
10/05/2010CA2425218C Pharmaceutical solutions of modafinil compounds
10/05/2010CA2407967C Tubulin binding ligands and corresponding prodrug constructs
10/05/2010CA2400479C Platelet adp receptor inhibitors
10/05/2010CA2394579C Combination of an ergoline and riluzole for preventing and treating motor neuron diseases
10/05/2010CA2393297C Polyhydroxystilbenes as antipsoriatic agents and protein kinase inhibitors
10/05/2010CA2391161C Pharmaceutical combinations comprising a p2t receptor antagonist and an anti-thrombotic agent
10/05/2010CA2370784C Endodontic fibers and methods of use therefor
10/05/2010CA2369595C Conjugate having a cleavable linkage for use in a liposome
10/05/2010CA2367138C Anti-inflammatory uses of manzamines
10/05/2010CA2364245C Water soluble group ia and iia double metal salt of(-)- hydroxycitric acid
10/05/2010CA2362930C Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use
10/05/2010CA2332000C Phytosterol compositions
10/05/2010CA2322516C Sustained release macrolide compositions
09/2010
09/30/2010WO2010111719A2 Melanogenesis inhibition by 3, 5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof
09/30/2010WO2010111718A2 Antiviral compounds and methods of use thereof
09/30/2010WO2010111713A2 N-linked glycan biosynthesis modulators
09/30/2010WO2010111710A1 Microalgal polysaccharide compositions
09/30/2010WO2010111673A1 Substituted bicyclic hcv inhibitors
09/30/2010WO2010111665A1 Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
09/30/2010WO2010111653A2 Modulating ires-mediated translation
09/30/2010WO2010111650A2 Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
09/30/2010WO2010111608A1 Foamyvirus vectors and methods of use
09/30/2010WO2010111587A1 Modulators of tdp-43 mediated toxicity
09/30/2010WO2010111574A1 Compounds as cannabinoid receptor ligands
09/30/2010WO2010111573A1 Compounds as cannabinoid receptor ligands
09/30/2010WO2010111572A1 Compounds as cannabinoid receptor ligands
09/30/2010WO2010111534A1 Fused ring inhibitors of hepatitis c
09/30/2010WO2010111530A1 Glycolipids as treatment for disease
09/30/2010WO2010111527A1 Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
09/30/2010WO2010111525A2 Treatment of carpal tunnel syndrome by injection of the flexor retinaculum
09/30/2010WO2010111518A1 Treatment and prevention of white matter injury with katp channel activators
09/30/2010WO2010111517A1 Stable polyelectrolyte coated nanoparticles
09/30/2010WO2010111504A2 Inhibition of glutaminase c
09/30/2010WO2010111503A2 RNA INTERFERENCE MEDIATED INHIBITION OF THE HIGH AFFINITY IGE RECEPTOR ALPHA CHAIN (FCεRLα) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
09/30/2010WO2010111488A1 Transdermal delivery
09/30/2010WO2010111471A2 RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
09/30/2010WO2010111468A2 RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
09/30/2010WO2010111464A1 RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
1 ... 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 2075 2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 ... 7860